Anaptysbio Inc Quick Ratio (ANAB) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Anaptysbio Inc   (NASDAQ: ANAB)

Anaptysbio Inc 's Quick Ratio

ANAB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the first quarter 2026, Quick Ratio fell to 7.24 below Anaptysbio Inc average.

Within Major Pharmaceutical Preparations industry 140 other companies have achieved higher Quick Ratio than Anaptysbio Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 211 to 462.

Explain Quick Ratio?
How much Cash & cash equivalents ANAB´s has?
What are ANAB´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ANAB Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1
Y / Y Current Liabilities Change -5.93 % -15.99 % -14.12 % -13.08 % 38.02 %
Y / Y Cash & cash equivalent Change -15.73 % -19.13 % -42.12 % -24.26 % -4.15 %
Quick Ratio MRQ 7.24 8.53 6.9 7.93 8.08
ANAB's Total Ranking # 462 # 211 # 412 # 326 # 308
Seq. Current Liabilities Change 8.31 % 1.33 % 7.57 % -20.32 % -3.28 %
Seq. Cash & cash equivalent Change -8.08 % 25.18 % -6.31 % -21.84 % -11.79 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 141
Healthcare Sector # 212
Overall Market # 462


Quick Ratio Statistics
High Average Low
37.56 15.41 6.9
(Dec 31 2021)   (Sep 30 2025)




Financial Statements
Anaptysbio Inc 's Current Liabilities $ 40 Millions Visit ANAB's Balance sheet
Anaptysbio Inc 's Cash & cash equivalent $ 286 Millions Visit ANAB's Balance sheet
Source of ANAB's Sales Visit ANAB's Sales by Geography


Cumulative Anaptysbio Inc 's Quick Ratio

ANAB's Quick Ratio for the trailling 12 Months

ANAB Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth -12.29 % -4.1 % 5.76 % 13.32 % 15.77 %
Y / Y Cash & cash equivalent TTM Growth -26.12 % -23.32 % -18.77 % -5.85 % -5.16 %
Quick Ratio TTM 7.64 7.87 7.99 8.82 9.07
Total Ranking TTM # 2790 # 2744 # 2774 # 2639 # 2661
Seq. Current Liabilities TTM Growth -1.68 % -4.48 % -3.68 % -3.04 % 7.5 %
Seq. Cash & cash equivalent TTM Growth -4.59 % -5.95 % -12.75 % -5.65 % -0.97 %

Quick ratio ranking by company, industry and sector >> Back to ANAB Financial Strength Comparisons >> Go to Compare ANAB Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in ANAB's Current Liabilities to $39.58 millions, cumulative Quick Ratio to 7.64 below the ANAB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 393 other companies have achieved higher Quick Ratio than Anaptysbio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2744 to 2790.

Explain Quick Ratio?
How much Cash & cash equivalents ANAB´s has?
What are ANAB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 394
Healthcare Sector # 792
Within the Market # 2790


trailing twelve months Quick Ratio Statistics
High Average Low
25.24 14.49 7.23
(Sep 30 2022)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Sagimet Biosciences inc   19.88 $ 104.539  Millions$ 5.258  Millions
Corvus Pharmaceuticals Inc   19.55 $ 236.714  Millions$ 12.110  Millions
Ligand Pharmaceuticals Incorporated  19.17 $ 779.405  Millions$ 40.667  Millions
Dyne Therapeutics Inc   18.97 $ 972.156  Millions$ 51.249  Millions
Agios Pharmaceuticals Inc   18.41 $ 737.038  Millions$ 40.040  Millions
Crinetics Pharmaceuticals Inc   18.17 $ 1,291.306  Millions$ 71.086  Millions
Relmada Therapeutics Inc  18.15 $ 233.963  Millions$ 12.892  Millions
Phio Pharmaceuticals Corp  17.93 $ 17.031  Millions$ 0.950  Millions
Amylyx Pharmaceuticals Inc   17.52 $ 279.768  Millions$ 15.966  Millions
Minerva Neurosciences Inc   17.42 $ 78.065  Millions$ 4.482  Millions
Lexicon Pharmaceuticals Inc   17.24 $ 170.658  Millions$ 9.898  Millions
Sellas Life Sciences Group Inc   16.60 $ 107.197  Millions$ 6.456  Millions
Pliant Therapeutics Inc   16.50 $ 170.892  Millions$ 10.359  Millions
Innoviva Inc   16.50 $ 603.085  Millions$ 36.558  Millions
Dianthus Therapeutics Inc   16.29 $ 617.109  Millions$ 37.884  Millions
Janux Therapeutics Inc   16.23 $ 956.386  Millions$ 58.915  Millions
Praxis Precision Medicines Inc   16.12 $ 786.865  Millions$ 48.806  Millions
Nuvalent Inc   15.88 $ 1,287.476  Millions$ 81.051  Millions
Oric Pharmaceuticals Inc   15.86 $ 281.932  Millions$ 17.771  Millions
Adc Therapeutics Sa  15.86 $ 231.008  Millions$ 14.567  Millions
Protagonist Therapeutics inc   15.86 $ 547.786  Millions$ 34.549  Millions
Aprea Therapeutics Inc   15.80 $ 46.466  Millions$ 2.941  Millions
Emmis Acquisition Corp   15.64 $ 0.782  Millions$ 0.050  Millions
Rezolute Inc   15.61 $ 120.268  Millions$ 7.704  Millions
Bioage Labs Inc   15.38 $ 243.457  Millions$ 15.827  Millions
An2 Therapeutics Inc   15.33 $ 85.288  Millions$ 5.562  Millions
Roivant Sciences Ltd   15.26 $ 4,291.833  Millions$ 281.244  Millions
Gri Bio Inc   15.01 $ 11.048  Millions$ 0.736  Millions
Ocular Therapeutix Inc   14.98 $ 666.699  Millions$ 44.513  Millions
Cogent Biosciences Inc   14.94 $ 866.378  Millions$ 57.981  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.